C4 Therapeutics, Inc.
CCCC
$4.26
-$0.14-3.18%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 6.15M | 11.02M | 11.23M | 6.46M | 7.24M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.15M | 11.02M | 11.23M | 6.46M | 7.24M |
| Cost of Revenue | 1.16M | -70.28M | 25.99M | 26.20M | 2.59M |
| Gross Profit | 4.99M | 81.30M | -14.76M | -19.73M | 4.65M |
| SG&A Expenses | 9.33M | 9.18M | 8.92M | 8.77M | 9.33M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.94M | 34.16M | 34.91M | 34.96M | 36.40M |
| Operating Income | -27.79M | -23.15M | -23.68M | -28.50M | -29.16M |
| Income Before Tax | -25.13M | -20.37M | -32.17M | -26.02M | -26.32M |
| Income Tax Expenses | -- | 121.00K | -- | -- | -- |
| Earnings from Continuing Operations | -25.13M | -20.49M | -32.17M | -26.02M | -26.32M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.13M | -20.49M | -32.17M | -26.02M | -26.32M |
| EBIT | -27.79M | -23.15M | -23.68M | -28.50M | -29.16M |
| EBITDA | -27.38M | -22.72M | -23.22M | -27.89M | -28.71M |
| EPS Basic | -0.20 | -0.18 | -0.44 | -0.37 | -0.37 |
| Normalized Basic EPS | -0.12 | -0.11 | -0.18 | -0.24 | -0.23 |
| EPS Diluted | -0.20 | -0.18 | -0.44 | -0.37 | -0.37 |
| Normalized Diluted EPS | -0.12 | -0.11 | -0.18 | -0.24 | -0.23 |
| Average Basic Shares Outstanding | 126.07M | 116.78M | 72.56M | 71.01M | 70.83M |
| Average Diluted Shares Outstanding | 126.07M | 116.78M | 72.56M | 71.01M | 70.83M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |